VACCELERATE志愿者登记库:一个便于临床试验入组的欧洲研究参与者数据库
为应对COVID-19临床试验受试者招募困难,科隆大学医院建立志愿者登记库并纳入欧洲VACCELERATE临床试验网络。截至2022年5月,问卷覆盖12个国家14种语言,超过36000名志愿者注册,主要来自德国;建立首年内为超过15000名志愿者匹配临床试验。登记库旨在成为欧洲未来临床试验潜在志愿者的共同入口。
要点
- VACCELERATE志愿者登记库通过在线问卷收集居住地、联系方式、年龄、性别、合并症、SARS-CoV-2感染与疫苗接种状态及可旅行距离等信息。
- 截至2022年5月,问卷在12个国家以14种语言提供,超过36000名志愿者注册,主要来自德国。
- 建立首年内,登记库已将超过15000名志愿者匹配至临床试验。
核心结论
- VACCELERATE志愿者登记库是面向有意参与COVID-19临床试验的欧洲居民的一个活跃单一入口,覆盖12个国家(奥地利、塞浦路斯、德国、希腊、爱尔兰、立陶宛、挪威、葡萄牙、西班牙、瑞典和土耳其)。
- 截至目前,仅德国已有超过15000名注册个体被连接至临床试验。
- 登记库目前正在另外5个国家(比利时、捷克共和国、匈牙利、以色列和荷兰)实施。
研究设计与样本
- 科隆大学医院首先在德国建立临床试验志愿者登记库,后纳入欧洲VACCELERATE临床试验网络并发展为欧洲志愿者登记库。
- 有意向的志愿者通过http://www.vaccelerate.eu/volunteer-registry访问注册问卷,提供当前国家和居住地区、联系方式(名、姓和电子邮件地址)、年龄、性别、合并症、既往SARS-CoV-2感染和疫苗接种状态以及愿意前往临床试验中心的最大距离。
- 登记库对成人和儿童开放,遵循国家法律同意要求。
主要发现
- 截至2022年5月,问卷在12个国家以14种语言提供。
- 截至目前,超过36000名志愿者注册,主要来自德国。
- 建立首年内,VACCELERATE志愿者登记库已将超过15000名志愿者匹配至临床试验。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The coronavirus disease 2019 (COVID-19) pandemic has evidenced the key role of vaccine design, obtention, production and administration to successfully fight against infectious diseases and to provide efficient remedies for the citizens. Although clinical trials were rapidly established during this pandemic, identifying suitable study subjects can be challenging. For this reason, the University Hospital Cologne established a volunteer registry for participation in clinical trials first in Germany, which has now been incorporated into the European VACCELERATE clinical trials network and grew to a European Volunteer Registry. As such, VACCELERATE's Volunteer Registry aims to become a common entry point for potential volunteers in future clinical trials in Europe. METHODS: Interested volunteers who would like to register for clinical trials in the VACCELERATE Volunteer Registry can access the registration questionnaire via http://www.vaccelerate.eu/volunteer-registry. Potential volunteers are requested to provide their current country and area of residence, contact information, including first and last name and e-mail address, age, gender, comorbidities, previous SARS-CoV-2 infection and vaccination status, and maximum distance willing to travel to a clinical trial site. The registry is open to both adults and children, complying with national legal consent requirements. RESULTS: As of May 2022, the questionnaire is available in 12 countries and 14 languages. Up to date, more than 36,000 volunteers have registered, mainly from Germany. Within the first year since its establishment, the VACCELERATE Volunteer Registry has matched more than 15,000 volunteers to clinical trials. The VACCELERATE Volunteer Registry will be launched in further European countries in the coming months. CONCLUSIONS: The VACCELERATE Volunteer Registry is an active single-entry point for European residents interested in COVID-19 clinical trials participation in 12 countries (i.e., Austria, Cyprus, Germany, Greece, Ireland, Lithuania, Norway, Portugal, Spain, Sweden and Turkey). To date, more than 15,000 registered individuals have been connected to clinical trials in Germany alone. The registry is currently in the implementation phase in 5 additional countries (i.e., Belgium, Czech Republic, Hungary, Israel and the Netherlands).
引用
- Salmanton-García J, Stewart FA, Heringer S, et al. VACCELERATE Volunteer Registry: A European study participant database to facilitate clinical trial enrolment. Vaccine. 2022. PMID: 35659449. doi:10.1016/j.vaccine.2022.05.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。